Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:HRB
NYSE:HRBConsumer Services

H&R Block Awards Spotlight AI Tools And Undervalued Share Price

H&R Block (NYSE:HRB) has been named Best Overall Tax Service for 2026. The company also received recognition for Best Use of AI for 2026. These awards highlight H&R Block's AI Tax Assist and Sidekick AI tools in client and professional tax preparation. H&R Block, trading at $30.88, now carries recent recognition as both Best Overall Tax Service and Best Use of AI for 2026, which directly ties to its core tax preparation business. Over 5 years, NYSE:HRB has a return of 77.6%, while the 1...
NasdaqGS:STX
NasdaqGS:STXTech

Seagate Technology Holdings (STX) Is Up 16.2% After AI-Driven Beat And Strong Storage Outlook

In late January 2026, Seagate Technology reported fiscal Q2 results that exceeded expectations, with revenue, adjusted earnings, and adjusted gross margin all improving, alongside constructive guidance for Q3. A key driver of this performance was accelerating demand for AI-related storage and the ramp-up of its HAMR-based Mozaic products, which management highlighted as central to its outlook. Next, we’ll examine how Seagate’s upbeat guidance tied to AI-focused storage demand could influence...
NYSE:RLX
NYSE:RLXTobacco

A Look At RLX Technology (NYSE:RLX) Valuation After Earnings Growth And Completed Share Buyback

Earnings and Buyback Set the Stage for RLX Technology (NYSE:RLX) RLX Technology (NYSE:RLX) is back in focus after reporting detailed fourth quarter and full year 2025 earnings, alongside the completion of a multi year share repurchase program that has reduced its share count. See our latest analysis for RLX Technology. Despite solid earnings headlines and the completed buyback, RLX Technology’s share price has eased recently. The 30 day and year to date share price returns show declines of...
NasdaqGS:AXON
NasdaqGS:AXONAerospace & Defense

Will Axon’s 2025 Beat, 2026 Outlook and Board Shift Change Axon Enterprise's (AXON) Narrative

Axon Enterprise recently reported strong Q4 2025 results, with revenue growth driven by demand for premium software, TASER 10, Axon Body 4, and counter-drone solutions, alongside upbeat guidance for 2026 and long-term 2028 revenue targets. At the same time, the company’s board will see change as director Julie Anne Cullivan has decided not to stand for re-election at the 2026 Annual Meeting, highlighting ongoing governance evolution alongside Axon’s product and earnings momentum. With Axon’s...
NYSE:HWM
NYSE:HWMAerospace & Defense

A Look At Howmet Aerospace’s Valuation After Its Recent Share Price Pullback

Context for Howmet Aerospace (HWM) after recent share moves Howmet Aerospace (HWM) has recently seen its share price move lower over the past week and month, while still showing a positive return in the past 3 months and over the past year. See our latest analysis for Howmet Aerospace. After a softer stretch that includes a 7.8% 1 month share price decline from a recent close of US$232.94, Howmet Aerospace still sits on a 12 month total shareholder return of 77.4%. This suggests that recent...
NasdaqGS:PTEN
NasdaqGS:PTENEnergy Services

Does Patterson UTI Energy (PTEN) Offer Value After Its Strong Recent Share Price Run?

This article examines whether Patterson-UTI Energy is attractively priced or already fully valued by focusing on what the current share price may be implying. The stock last closed at US$10.72, with returns of 8.8% over 7 days, 35.4% over 30 days, 65.7% year to date, 34.6% over 1 year, 12.6% over 3 years and 67.0% over 5 years. These figures may signal shifting views on its prospects and risk. Recent coverage has highlighted Patterson-UTI Energy as an energy services provider. This includes...
XTRA:DBK
XTRA:DBKCapital Markets

Deutsche Bank (XTRA:DBK) Valuation After Leadership Shake Up And Technology Focus Shift

Deutsche Bank (XTRA:DBK) has put boardroom change at the center of its story, adding DWS chief Stefan Hoops to the Management Board and naming Marie Jeanne Deverdun Chief Technology, Data and Innovation Officer. See our latest analysis for Deutsche Bank. That board refresh and the recent flurry of long dated bond issuance come after a sharp short term pullback, with a 30 day share price return of 17.04% decline and year to date share price return of 25.06% decline. At the same time, the 5...
SEHK:9660
SEHK:9660Software

Horizon Robotics (SEHK:9660) Heavy C¥5.2b Loss Tests Bullish Profitability Narratives

Horizon Robotics (SEHK:9660) has reported FY 2025 first half results with revenue of C¥1.6b and a basic EPS loss of C¥0.42, setting a clear focus on how growth is feeding through to the bottom line. The company has seen revenue move from C¥934.6m in 1H 2024 to C¥1.4b in 2H 2024 and C¥1.6b in 1H 2025, while EPS has swung from a loss of C¥1.81 in 1H 2024 to a profit of C¥1.17 in 2H 2024 before reverting to a loss, so investors are watching how quickly these top line gains can translate into...
NYSE:WT
NYSE:WTCapital Markets

Is It Too Late To Consider WisdomTree (WT) After A 59% One Year Rally?

If you are wondering whether WisdomTree at US$13.86 still offers value after a strong run, a useful starting point is to understand how its current price lines up against different valuation measures. The stock has pulled back 8.5% over the past week and 16.3% over the past month. Even so, it is still up 10.8% year to date and 59.4% over the last year, as well as a very large gain over five years of 153.4%. Recent news flow around WisdomTree has focused on its position within the broader...
NYSE:OSCR
NYSE:OSCRInsurance

Assessing Oscar Health (OSCR) Valuation After Mixed Returns And A Possible Undervaluation Gap

Oscar Health stock snapshot after recent trading moves Oscar Health (OSCR) has seen mixed share performance, with a 1.9% decline over the past day, a 2.3% gain over the past week, and negative returns over the past month and past 3 months. See our latest analysis for Oscar Health. At a share price of $13.30, Oscar Health’s recent 1 day and 90 day share price declines sit against a modest 1 year total shareholder return of 2.9% and a very large 3 year total shareholder return, suggesting...
SEHK:1088
SEHK:1088Oil and Gas

Assessing China Shenhua Energy’s Valuation After Mixed February 2026 Operating Trends

China Shenhua Energy (SEHK:1088) attracted fresh attention after releasing its February 2026 operating update, which highlighted softer monthly coal volumes but slightly higher year to date coal and polypropylene sales, alongside mixed power generation figures. See our latest analysis for China Shenhua Energy. The share price has climbed to HK$48.82, alongside a 23.1% year-to-date share price return and a very large 5-year total shareholder return. This suggests that momentum has been...
TSE:7751
TSE:7751Tech

Will Canon’s High-Reuse U.S. Remanufacturing Push Change Canon's (TSE:7751) Circular-Economy Narrative

In March 2026, Canon Inc. and its U.S. affiliates announced the expansion of Canon’s global multifunction device remanufacturing business to Canon Virginia, applying standardized processes and proprietary technologies developed in Japan and Germany to serve the U.S. market. This move deepens Canon’s circular-economy footprint by using operational data-driven parts selection and achieving an estimated parts reuse rate above 90% per remanufactured unit, aligning cost efficiency with...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

A Look At Expedia Group (EXPE) Valuation After OpenAI’s ChatGPT Booking Decision

Expedia Group (EXPE) is back in focus after OpenAI confirmed ChatGPT will not support direct travel bookings. This has eased fears that AI tools could bypass online travel agencies and has reframed how investors look at Expedia’s role in AI driven trip planning. See our latest analysis for Expedia Group. The share price reaction to the OpenAI decision fits into a mixed pattern, with a 19.45% 1 month share price return and 5.17% over 7 days, set against a 15.38% year to date decline. At the...
SEHK:867
SEHK:867Pharmaceuticals

China Medical System Wins Desidustat Approval Raising Nephrology Growth Questions

China Medical System Holdings (SEHK:867) has received marketing approval in China for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis chronic kidney disease patients. The approval adds a new drug to the company’s nephrology portfolio and targets a major unmet medical need in China. China Medical System Holdings is drawing fresh attention after this new approval, with the share price at HK$13.49 and a 1 year return of 81.4%. The stock has also seen a 6.1% gain over...
CPSE:PNDORA
CPSE:PNDORALuxury

A Look At Pandora’s (CPSE:PNDORA) Valuation After Dividend Approval And AGM Governance Changes

Pandora AGM decisions put income and governance in focus Pandora (CPSE:PNDORA) used its 11 March 2026 AGM to approve a DKK 22.00 per share dividend, amend article 7.3 of its Articles of Association, and confirm that board member Christian Frigast will step down. See our latest analysis for Pandora. Pandora's recent AGM decisions on dividends, governance and board composition arrive after a sharp loss of momentum, with a 30 day share price return of 18% and a 1 year total shareholder return of...
TSX:ARIS
TSX:ARISMetals and Mining

Aris Mining (TSX:ARIS) Earnings Jump on Expansion Push Are Higher Margins Justifying the Strategy?

Aris Mining Corporation recently reported its fourth quarter and full-year 2025 results, with Q4 sales rising to US$308.57 million and net income to US$50.86 million, and full-year sales reaching US$927.66 million alongside net income of US$78.35 million. The company’s full-year diluted earnings per share from continuing operations increased to US$0.41, suggesting that stronger operational performance is flowing through to shareholders’ bottom-line results. With this jump in full-year...
BME:BBVA
BME:BBVABanks

A Look At BBVA (BME:BBVA) Valuation After Recent Share Price Weakness

Banco Bilbao Vizcaya Argentaria (BME:BBVA) has drawn attention after recent share price weakness, with the stock showing negative returns over the past month and past 3 months despite a positive 1 year total return. See our latest analysis for Banco Bilbao Vizcaya Argentaria. Despite the recent 1 month and 3 month share price declines, the current share price of €17.915 sits against a strong backdrop, with 1 year, 3 year and 5 year total shareholder returns all firmly positive. Recent...
NYSE:SQM
NYSE:SQMChemicals

A Look At SQM (NYSE:SQM) Valuation As It Proposes A Higher 2025 Dividend Payout

Sociedad Química y Minera de Chile (SQM) has flagged a meaningful shift in its payout approach, with the Board set to recommend a 50% dividend of 2025 net income, compared with the existing 30% policy. See our latest analysis for Sociedad Química y Minera de Chile. At a share price of US$74.66, Sociedad Química y Minera de Chile has delivered a 30 day share price return of 3.12% and a 90 day share price return of 8.58%. Its 1 year total shareholder return of 68.76% points to strong momentum...
NYSE:VNO
NYSE:VNOOffice REITs

Is It Time To Reconsider Vornado Realty Trust (VNO) After Its Recent Share Price Slide?

For investors considering whether Vornado Realty Trust at around US$26.48 reflects enough potential or already embeds too much optimism, this article breaks down what the current share price really represents. The stock has had a mixed run, with a 1.7% gain over the last 7 days, an 8.8% decline over the last 30 days, a 20.8% decline year to date, a 29.9% decline over 1 year, and a 114.6% return over 3 years, compared with a 32.1% decline over 5 years. Recent coverage around Vornado Realty...
NYSE:PBI
NYSE:PBICommercial Services

Will Pitney Bowes’ (PBI) Cash Windfall, Buybacks and Review Shift Its Structurally Challenged Narrative

Pitney Bowes recently reported generating US$358.3 million in free cash flow in 2025 while spending US$378 million on share repurchases, and its new CEO Kurt Wolf acknowledged past Presort pricing missteps as the company proceeds with a Phase 2 strategic review due by the end of Q2 2026. This combination of robust cash generation, aggressive buybacks, and a pending strategic review has sharpened attention on how Pitney Bowes might extract standalone value from a structurally challenged...
NYSE:NET
NYSE:NETIT

Cloudflare (NET) Valuation Check After Coinbase And SentinelOne AI Partnership Momentum

Why Cloudflare’s latest partnerships matter for investors Cloudflare (NET) is back in focus after reports of a partnership with Coinbase on stablecoin-based AI agent transactions, along with a deeper SentinelOne integration for AI driven threat detection and response. Taken together, these developments place Cloudflare’s network and security data at the center of two areas investors are watching closely: automated cybersecurity operations, and machine driven payments. They also raise new...
NYSE:BYD
NYSE:BYDHospitality

Is It Time To Reassess Boyd Gaming (BYD) After Mixed Returns And Low P/E Ratio

If you are wondering whether Boyd Gaming's current share price reflects its real worth, the recent numbers provide a useful starting point for a closer look at valuation. The stock last closed at US$83.06, with returns of 2.2% over 7 days, a 0.2% decline over 30 days, a 3.6% decline year to date, 23.7% over 1 year, 42.8% over 3 years, and 44.1% over 5 years. Recent coverage has focused on Boyd Gaming's position in the broader consumer services space and how investors are weighing its long...
LSE:GSK
LSE:GSKPharmaceuticals

GSK’s Lynavoy Approval And Licensing Deal Reframe Rare Disease Value Case

GSK (LSE:GSK) has received FDA approval for Lynavoy (linerixibat) as the first treatment in the US for cholestatic pruritus in primary biliary cholangitis. The approval is based on Phase III data and targets a rare liver disease symptom that significantly affects quality of life. GSK has signed a licensing agreement granting Alfasigma exclusive worldwide rights to develop, manufacture, and commercialise linerixibat. Lynavoy adds a rare disease medicine to GSK's portfolio, which already...
NYSE:NATL
NYSE:NATLDiversified Financial

Did Noteholder-Backed Indenture Changes and Earnings Beat Just Shift NCR Atleos' (NATL) Investment Narrative?

On March 11, 2026, NCR Atleos Corporation announced that holders of a majority of its 9.500% Senior Secured Notes due 2029 consented to amendments to the governing indenture, enabling the company, its guarantor subsidiaries, and the trustee to execute a binding supplemental indenture effective immediately. This successful consent solicitation comes shortly after NCR Atleos reported quarterly results with revenue in line with expectations but earnings ahead of forecasts, highlighting the...